|
WASTING
Table of Contents
HIV
Wasting: Incidence in the HAART Era - Nutrition for Healthy
Living (NFHL) Study
HIV
Wasting: Incidence in the NFHL Cohort (N=466)
HIV
Wasting: Weight Loss in the NFHL Cohort (N=497)
HIV
Wasting: Relationship of Incidence to HAART Use in the NFHL
Cohort (N=633)
HIV
Wasting: Effect of HAART
HIV
Wasting: Loss of Lean Body Mass (LBM) and Fat Mass (FM)
HIV
Wasting: Is It Wasting or Fat Atrophy?
HIV
Wasting: Etiology
of Weight Loss
HIV
Wasting: Effects
HIV
Wasting: Definition
HIV
Wasting: Initial Patient Evaluation
HIV
Wasting: Initial Patient Evaluation – Suggested Questions
HIV
Wasting: Initial Patient Evaluation – Body Composition
Measurements
HIV
Wasting: Bioelectrical Impedance Analysis (BIA)
HIV
Wasting: BIA
Studies in HIV-Infected Patients
HIV
Wasting: Other Body Composition Techniques
HIV
Wasting: Validation and Advantages of BIA
HIV
Wasting: Initial Patient Evaluation – Laboratory Tests
HIV
Wasting: Follow-Up Visit
HIV
Wasting: General Patient Management
HIV
Wasting: Interventions and Treatment
HIV
Wasting: Growth
Hormone rhGH[m] (Serostim®)1,2
HIV
Wasting: Initial Therapy with rhGH[m] (Serostim®)
HIV
Wasting: Placebo-Controlled
Trial of rhGH[m] (Serostim®)
HIV
Wasting: Change in Body Composition with rhGH[m] (Serostim®)
Therapy
HIV
Wasting: Testosterone for Hypogonadal Patients1-4
HIV
Wasting: Management and Treatment Algorithm
HIV
Wasting: Anabolic Agents for Non-Hypogonadal Patients1-5
HIV
Wasting: Nandrolone (Deca Durabolin®)
HIV
Wasting: Oxandrolone (Oxandrin®)
HIV
Wasting: Anabolic Agents1-6
HIV
Wasting: Appetite Stimulants for Anorexia1-6
HIV
Wasting: Dronabinol (Marinol®)1, 2
HIV
Wasting: Megestrol Acetate (Megace®)
HIV
Wasting: Megestrol Acetate (Megace®) –
Study Results
HIV
Wasting: Adjunctive Treatments and Interventions
HIV
Wasting: Progressive Resistance Exercise (PRE)
HIV
Wasting: Post-Treatment
Visits – Every 3 Months
HIV
Wasting: Expected Clinical Outcomes
HIV
Wasting: Summary and Conclusions
|